CO5300464A1 - Metodo para regular la angiogenesis utilizando proteina ryk - Google Patents

Metodo para regular la angiogenesis utilizando proteina ryk

Info

Publication number
CO5300464A1
CO5300464A1 CO01036462A CO01036462A CO5300464A1 CO 5300464 A1 CO5300464 A1 CO 5300464A1 CO 01036462 A CO01036462 A CO 01036462A CO 01036462 A CO01036462 A CO 01036462A CO 5300464 A1 CO5300464 A1 CO 5300464A1
Authority
CO
Colombia
Prior art keywords
sec
protein
ryk
variant
site
Prior art date
Application number
CO01036462A
Other languages
English (en)
Spanish (es)
Inventor
Steve Roczniak
A Dubois-Strin Nathalie
Alya Zolotorev
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CO5300464A1 publication Critical patent/CO5300464A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO01036462A 2000-05-10 2001-05-09 Metodo para regular la angiogenesis utilizando proteina ryk CO5300464A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
CO5300464A1 true CO5300464A1 (es) 2003-07-31

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01036462A CO5300464A1 (es) 2000-05-10 2001-05-09 Metodo para regular la angiogenesis utilizando proteina ryk

Country Status (13)

Country Link
EP (1) EP1287121A2 (https=)
JP (1) JP2004527206A (https=)
AR (1) AR028424A1 (https=)
AU (1) AU2001261343A1 (https=)
CA (1) CA2408349A1 (https=)
CO (1) CO5300464A1 (https=)
DO (1) DOP2001000164A (https=)
EC (1) ECSP014068A (https=)
GT (1) GT200100079A (https=)
PE (1) PE20011218A1 (https=)
SV (1) SV2002000442A (https=)
UY (1) UY26696A1 (https=)
WO (1) WO2001085789A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471934A2 (en) * 2002-02-06 2004-11-03 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
TW202315894A (zh) * 2021-08-18 2023-04-16 美國加利福尼亞大學董事會 抗受體相關酪胺酸激酶（ｒｙｋ）抗體及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646129A4 (en) * 1992-05-11 1995-07-19 Ludwig Inst Cancer Res MOLECULES, WHICH ARE SIMILAR TO THE TYROSIN KINASE OF THE RECEPTOR TYPE (01/13/94).
AU4606196A (en) * 1994-12-23 1996-07-19 Ludwig Institute For Cancer Research Assay, receptor proteins and ligands
WO1999064589A1 (en) * 1998-06-11 1999-12-16 Astrazeneca Ab Human receptor tyrosine kinase
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Also Published As

Publication number Publication date
WO2001085789A3 (en) 2002-05-16
WO2001085789A2 (en) 2001-11-15
GT200100079A (es) 2001-12-31
JP2004527206A (ja) 2004-09-09
AU2001261343A1 (en) 2001-11-20
EP1287121A2 (en) 2003-03-05
UY26696A1 (es) 2001-12-28
PE20011218A1 (es) 2002-02-01
DOP2001000164A (es) 2002-05-15
ECSP014068A (es) 2002-02-25
SV2002000442A (es) 2002-07-03
CA2408349A1 (en) 2001-11-15
AR028424A1 (es) 2003-05-07

Similar Documents

Publication Publication Date Title
AR021448A1 (es) Metodo para producir un polipeptido quimerico
AR012531A1 (es) Composicion para cuidado personal, composicion para repasador y metodo para minimizar o reducir la comezon o quemado de la piel a causa de composicionespara cuidado personal que contienen acido.
ES2183945T3 (es) Composiciones para mejorar el aporte de un agente por electrotransporte.
ES2194376T3 (es) Preparacion especifica de sitio de conjugados de polietilenglicol-grf.
PE20110236A1 (es) Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina
BR9609393A (pt) Composição injetável de colágeno; segmentos de fibra de colágeno reconstituìdos.
DE69728172D1 (de) Mikroemulsion und verfahren
DE69628290D1 (de) Methoden und zusammensetzungen zur lipidisierung hydrophiler moleküle
ATE208612T1 (de) Biologisch erodierbare vorrichtung zur verabreichung von wirkstoffen
DE50107705D1 (de) Neue pharmazeutische zusammensetzung zur verabreichung von n-0923
AR023529A1 (es) Una composicion champu acondicionadora del cabello y un metodo para acondicionar el cabello
BR0108734A (pt) Composições antimicrobiais ácidas para tratar alimento e superfìcies de contato do alimento e métodos para uso das mesmas
GT199800085A (es) Sal tartrato de un dipeptido sustituido.
ES2141229T3 (es) Productos farmaceuticos de proteinas y peptidos modificados.
ES2096872T3 (es) Composiciones limpiadoras acuosas acidas.
TW200518767A (en) Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
ES2112669T3 (es) Utilizacion de acidos carboxilicos hidroxilados para el tratamiento de las u¦as
ES2183332T3 (es) Aminoacidos biciclicos aromaticos.
AR018357A1 (es) Acido petroselinico en una composicion y en un metodo para reducir o eliminar la irritacion o la picazon de la piel inducida por los alfa-hidroxiacidos
DK0953576T3 (da) Aktivt hedgehog-proteinkonjugat, fremgangsmåde til fremstilling heraf og anvendelse
NO20073914L (no) Biologisk aktive peptider
CO5570658A2 (es) Composicion y metodo para el tratamiento de la diabetes
CO5300464A1 (es) Metodo para regular la angiogenesis utilizando proteina ryk
AR033979A1 (es) Metodo para preparar un polipeptido il-18 fisiologicamente activo
ES2197840T1 (es) Metodo para producir y usar nuevas defensinas humanas como proteinas biologicamente activas para tratar infecciones y otras enfermedades.